( 4-15-55 Terms and conditions of use ...)Addex Achieves Statistically Significant Outcome in Phase IIa,Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease,Health
Navigation Links
| HOME >> MEDICINE >> TECHNOLOGY |
Addex Achieves Statistically Significant Outcome in Phase IIa,Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
4-15-55
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights
reserved.
A United Business Media Company
'"/>
Related medicine technology :
1. Addex Reports Positive Results in Phase IIa Clinical Trial With ADX10059 in Migraine
2. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
3. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
4. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
7. Mymetics HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model
8. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
9. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
11. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
Post Your Comments:
Breaking Medicine Technology:Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 2Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 3Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 4Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 5Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 6Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 7Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 8Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 9Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 2Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 3Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 4Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 5Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 6Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 7Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 8Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 9Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 2Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 3Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 4Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 5Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 6Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 7Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 8Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 9Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 10Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 11Nearly 9 in 10 Seniors Satisfied With Medigap 48743 1Nearly 9 in 10 Seniors Satisfied With Medigap 48743 2Nearly 9 in 10 Seniors Satisfied With Medigap 48743 3A Robot That Reads Your Mind 3F 48740 1A Robot That Reads Your Mind 3F 48740 2The Stress of Sudden Fame Made Anxiety Attacks Headline News 48736 1The Stress of Sudden Fame Made Anxiety Attacks Headline News 48736 2
Other Medicine Technology:New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 2New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 3New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 4New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 5New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 6New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 7U. of Md. Researchers to Develop Devices to Revolutionize Drug Research 2U. of Md. Researchers to Develop Devices to Revolutionize Drug Research 3U. of Md. Researchers to Develop Devices to Revolutionize Drug Research 4U. of Md. Researchers to Develop Devices to Revolutionize Drug Research 5
Breaking Medicine News(10 mins):Health News:New Fun Xercise Bike Enables You to Work Out and Play 2Health News:Ceridian Web Forum to Prepare Employers for Health Care Reform 2Health News:Ceridian Web Forum to Prepare Employers for Health Care Reform 3Health News:Robert Allard, Law Firm of Corsiglia, McMahon & Allard Named 2009 Trial Lawyer of the Year 2Health News:World-Renowned Vascular Surgeon to Conduct Training at Harvard Medical School Site on Non-Invasive Treatment of Veins 2Health News:World-Renowned Vascular Surgeon to Conduct Training at Harvard Medical School Site on Non-Invasive Treatment of Veins 3Health News:Beckman Coulter to Host Annual Business Review 2
[0] New Fun Xercise Bike Enables You to Work Out and Play[0] Ceridian Web Forum to Prepare Employers for Health Care Reform[0] Robert Allard, Law Firm of Corsiglia, McMahon & Allard Named 2009 Trial Lawyer of the Year[0] World-Renowned Vascular Surgeon to Conduct Training at Harvard Medical School Site on Non-Invasive Treatment of Veins[0] Beckman Coulter to Host Annual Business Review
Other Medicine News:Health News:Empire BlueCross BlueShield Appoints Chief Medical Officer 2Health News:'Positively Conscious: An Enlightened Look At Life' 2Health News:PatentStorm Releases U.S. Patent Applications and Other Features 2Health News:Former Mayor of Indianapolis to Serve as a Senior Strategic Advisor to McKenna Long & Aldridge LLP's Global Infrastructure Finance and Public-Private Partnerships Practice 2Health News:Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting 2Health News:Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting 3Health News:Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting 4Health News:Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting 5Health News:Agile Therapeutics Abstracts on Lead Product, AG200-15 Accepted by ACOG 2Health News:Agile Therapeutics Abstracts on Lead Product, AG200-15 Accepted by ACOG 3Health News:Agile Therapeutics Abstracts on Lead Product, AG200-15 Accepted by ACOG 4
Empire BlueCross BlueShield Appoints Chief Medical Officer'Positively Conscious: An Enlightened Look At Life'PatentStorm Releases U.S. Patent Applications and Other FeaturesFormer Mayor of Indianapolis to Serve as a Senior Strategic Advisor to McKenna Long & Aldridge LLP's Global Infrastructure Finance and Public-Private Partnerships PracticeCelator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology MeetingAgile Therapeutics Abstracts on Lead Product, AG200-15 Accepted by ACOG
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |